| Date |
Title |
| 2023 |
| April 30 |
Update: Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies (Effective date: April 30, 2023)
– Questions and Answers for Pharmacies |
| April 21 |
Executive Officer Notice: Prescribing & Dispensing Publicly Funded Paxlovid in Ontario Pharmacies (No changes from December 12)
– Updated: Frequently Asked Questions for Pharmacies |
| April 13 |
Executive Officer Notice: Temporary PINs for Humalog® (insulin lispro): Shortage of the insulin lispro biosimilar (Admelog®)
(Effective date: March 31, 2023) |
| April 6 |
Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies
– Frequently Asked Questions |
| April 3 |
Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Extend the Reconciliation Adjustment to Pharmacy Payments
(Effective date: April 1, 2023) |
| March 31 |
Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020
(Effective date: April 1, 2023) |
| March 13 |
Executive Officer Notice: Biosimilar Policy
(Effective date: March 10, 2023)
– Questions and Answers for Pharmacies
– Patient Support Programs for Biosimilars
(Effective date March 29, 2023) |
| March 6 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date March 6, 2023)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Billing
(Effective date March 6, 2023)
– Updated: Questions and Answers for Pharmacies
– Updated: Questions and Answers for Patients |
| February 28 |
Notice: Proposed Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Extend Reconciliation Adjustment to Pharmacy Payments |
| February 6 |
* Please refer to entry posted on April 21, 2023 for the latest EO Notice and FAQs.
Executive Officer Notice: Prescribing & Dispensing Publicly Funded Paxlovid in Ontario Pharmacies (No changes from December 12)
– Updated: Frequently Asked Questions for Pharmacies |
| January 25 |
Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies |
| January 19 |
Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #7
– Ontario Drug Programs Reference Manuals |
| 2022 |
| December 22 |
* Please refer to entry posted on April 30, 2023 for the latest updated EO Notice.
Executive Officer Notice: Funding for Minor Ailment Services in Ontario Pharmacies
(Effective date: January 1, 2023)
– Questions and Answers for Pharmacies |
| December 21 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date December 21, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Billing
(Effective date December 21, 2022)
– Updated: Questions and Answers for Pharmacies
– Updated: Questions and Answers for Patients |
| December 15 |
Executive Officer Notice: Administration of Publicly Funded Influenza Vaccine in Ontario Pharmacies
(No change from September 20, 2022)
– Updated: Questions and Answers for Pharmacies |
| December 12 |
Updated: Executive Officer Notice: Supplying of Publicly Funded Evusheld™ for Pre-Exposure Prophylaxis of COVID-19 in Ontario Pharmacies
(Effective date December 12, 2022)
– Updated: Questions and Answers for Pharmacies |
| December 12 |
* Please refer to entry posted on April 21, 2023 for the latest EO Notice and FAQs.
Executive Officer Notice: Prescribing & Dispensing Publicly Funded Paxlovid™ in Ontario Pharmacies
(Effective date December 12, 2022)
– Updated: Questions and Answers for Pharmacies |
| December 12 |
Executive Officer Notice: Updated Quarterly Report Back Form for the Ontario Naloxone Program for Pharmacies (ONPP) |
| November 22 |
Executive Officer Notice: Replacement of ONE Mail Direct Email Service with Microsoft Office 365 Email Account
– Questions and Answers for Pharmacies
|
| November 8 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date November 8, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Billing
(Effective date November 8, 2022)
– Updated: Questions and Answers for Pharmacies
– Updated: Questions and Answers for Patients |
| October 17 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date October 17, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Billing
(Effective date October 17, 2022)
– Updated: Questions and Answers for Pharmacies
– Updated: Questions and Answers for Patients |
| October 6 |
* Please refer to entry posted on January 25, 2023 for the latest updated EO Notice
Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies
– Questions and Answers for Pharmacists
– Questions and Answers for Patients |
| October 3 |
*Please refer to entry posted on December 12, 2022 for the updated EO Notice and Qs & As.
Notice from the Executive Officer: Supplying of Publicly Funded Evusheld™ for Pre-Exposure Prophylaxis of COVID-19 in Ontario Pharmacies
– Frequently Asked Questions |
| September 26 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date September 26, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Billing
(Effective date September 26, 2022)
– Updated: Questions and Answers for Pharmacies
– Updated: Questions and Answers for Patients |
| September 20 |
*Please refer to entry posted on December 15, 2022 for the updated EO Notice and Qs & As.
Notice from the Executive Officer: Pharmacy administration of publicly funded influenza vaccines and claims submission using the Health Network System, 2022-2023
– Frequently Asked Questions |
| September 12 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date September 12, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Billing
(Effective date September 12, 2022)
– Updated: Questions and Answers for Pharmacies
– Updated: Questions and Answers for Patients |
| September 1 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date September 1, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Billing
(Effective date September 1, 2022)
– Updated: Questions and Answers for Pharmacies
– Updated: Questions and Answers for Patients |
| August 22 |
Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #6
– Ontario Drug Programs Reference Manual |
| August 9 |
* Please refer to entry posted on January 25, 2023 for the latest updated EO Notice
Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies
– Questions and Answers for Pharmacies
– Questions and Answers for Patients |
| August 8 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date August 8, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date August 8, 2022)
Updated: Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients (No change from the July 28, 2022 update) |
| July 28 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date July 28, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date July 28, 2022)
Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients |
| July 28 |
Executive Officer Notice: Policy for Methadone Maintenance Treatment Reimbursement under the Ontario Drug Benefit Program
Questions and Answers for Pharmacies: Policy for Methadone Maintenance Treatment (MMT) Reimbursement under the Ontario Drug Benefit Program |
| July 26 |
* Please refer to entry posted on February 6, 2023 for the latest EO Notice and FAQs.
Executive Officer Notice: Supplying of Publicly Funded Oral Antiviral COVID-19 Treatment in Ontario Pharmacies
(Effective date: April 12, 2022, Updated July 26, 2022)
Questions and Answers for Pharmacies |
| July 14 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date July 14, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date July 14, 2022)
Updated: Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients |
| June 24 |
Notice from the Executive Officer: Temporary Benefit Nutrition Products: Shortage of infant formulas for infants with food allergies and certain medical conditions |
| May 31 |
Update to the Executive Officer Notice of interim change to Extemporaneous Preparations Policy for Anti-infectives |
| May 13 |
Notice from the Executive Officer:
Pan-Canadian Select Molecules Price Initiative for Generic Drugs |
| May 2 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 2, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date May 2, 2022)
Updated: Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients
|
| May 1 |
Executive Officer Notice: Update to Home Care Eligibility under the Ontario Drug Benefit Program |
| April 25 |
* Please refer to entry posted on February 6, 2023 for the latest EO Notice and FAQs.
Executive Officer Notice: Supplying of Publicly Funded Oral Antiviral COVID-19 Treatment in Ontario Pharmacies
(Effective date: April 12, 2022, Updated April 25, 2022)
– Questions and Answers for Pharmacists |
| April 12 |
* Please refer to entry posted on February 6, 2023 for the latest EO Notice and FAQs.
Executive Officer Notice: Supplying of Publicly Funded Oral Antiviral COVID-19 Treatment in Ontario Pharmacies
(Effective date: April 12, 2022)
– Questions and Answers for Pharmacists |
| April 12 |
Updated: Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies –Eligibility |
| April 8 |
Executive Officer Notice: Providing Support for Persons with an Emergency Authorization for Humanitarian Reasons under Ontario Public Drug Programs
(Effective Date: April 6, 2022) |
| April 7 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date April 7, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date April 7, 2022)
Updated: Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients
|
| April 1 |
Updated – Notice from the Executive Officer: Reimbursement and Claims Submission using the Health Network System relating to Drugs for Medical Assistance in Dying
– Updated – Frequently Asked Questions for Dispensers: Dispensing Publicly Funded Kits for Medical Assistance in Dying (MAID) and Claims Submission using the Health Network System |
| March 25 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date March 25, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date March 25, 2022)
Updated: Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients
|
| March 21 |
* Please refer to entry posted on January 25, 2023 for the latest updated EO Notice
Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies
– Questions and Answers for Pharmacists |
| March 17 |
Executive Officer Notice: Reconciliation Adjustment Percentages for 2022/23 to Improve the Value of Pharmacy Payments |
| March 15 |
Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #5
– Ontario Drug Programs Reference Manual |
| March 7 |
Executive Officer Notice: Health Network System Changes to Reimbursement of Blood Glucose Test Strips |
| February 22 |
Notice from the Executive Officer: Funding of Insulin Aspart and Insulin Glargine under the Ontario Drug Benefit Program
– Insulin glargine Frequently Asked Questions
– Insulin aspart Frequently Asked Questions |
| February 18 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date February 18 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date February 18 2022)
Updated: Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients
|
| February 18 |
Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020
– Questions and Answers for Pharmacists |
| February 4 |
* Please refer to entry posted on January 25, 2023 for the latest updated EO Notice Updated: Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies - Eligibility |
| January 17 |
* Please refer to entry posted on January 25, 2023 for the latest updated EO Notice
Updated Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies
|
| January 13th |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date January 13th, 2022)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date January 13th, 2022)
Updated: Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients
|
| January 11 |
Executive Officer Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation |
| 2021 |
| December 31 |
Updated: Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies – Eligibility |
| December 20 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date December 20th, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date December 20th, 2021)
Updated: Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients
|
| December 17 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date December 17th, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date December 17th, 2021)
Updated: Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients
|
| December 7 |
UPDATE: Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System, 2021-2022
– Frequently Asked Questions |
| December 2nd |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated:Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date December 2nd, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date December 2nd, 2021)
Updated: Questions and Answers for Pharmacies
Updated: Questions and Answers for Patients |
| December 1 |
Updated: Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies – Eligibility |
| November 27 |
Updated: Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies – Eligibility
|
| November 25th |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date November 25th, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date November 25th, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| November 18 |
* Please refer to entry posted on March 21, 2022 for the latest updated EO Notice on Eligibility
Updated Notice from the Executive Officer: Publicly Funded COVID-19 Testing Services in Ontario Pharmacies: Eligibility Criteria
– Questions and Answers for Pharmacists |
| November 17 |
*Please refer to entry posted on December 7, 2021 for the latest updated EO Notice Update to Executive Officer Notice: Administration of the Publicly Funded Influenza Vaccines in Ontario Pharmacies – Pharmacy Technicians |
| November 3rd |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date November 3rd, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date November 3rd, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| October 27 |
Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #4
– Ontario Drug Programs Reference Manual |
| October 8 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date October 8, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date October 8, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| October 8 |
*Please refer to entry posted on December 7, 2021 for the latest updated EO Notice
Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System, 2021-2022
– Frequently Asked Questions |
| October 1st |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date October 1, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date October 1, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| September 22 |
Updated Executive Officer Notice: Publicly Funded COVID-19 Antigen Point-of-Care Testing in Ontario Pharmacies
– Updated Questions and Answers for Pharmacists |
| September 21 |
Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020
(Effective date September 27, 2021)
– Frequently Asked Questions |
| September 8 |
Executive Officer Notice: Publicly Funded COVID-19 Antigen Point-of-Care Testing in Ontario Pharmacies
– Questions and Answers for Pharmacists |
| September 8 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies - Eligibility
(Effective date September 8, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date September 8, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| September 1 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date September 1, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date September 1, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| August 27 |
* Please refer to entry posted on November 18 2021 for the latest updated EO Notice on Eligibility
Updated Executive Officer Notice: Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria |
| August 18 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date August 18, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date August 18, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients (FYI: No change from July 5 posting) |
| July 5 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date July 5, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date July 5, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| June 25 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 25, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date June 25, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| June 17 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 17, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| June 14 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 14, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date June 14, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| June 14 |
Executive Officer Notice: Improved Access to Exceptional Access Program Drugs for Ontarians Living Near Manitoba and Quebec Borders under the Ontario Drug Benefit Program
– Questions and Answers |
| June 4 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date June 4, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date June 4, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| June 4 |
Executive Officer Notice: The Ontario Drug Programs Reference Manual, Revision #3
– Ontario Drug Programs Reference Manual |
| May 31 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 31, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date May 31, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| May 31 |
* Please refer to entry posted on August 27 2021 for the latest updated EO Notice on Eligibility
Updated Executive Officer Notice: Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria |
| May 23 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 23, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date May 13, 2021)
(FYI: No change from May 13 posting)
–Updated: Questions and Answers for Pharmacists (FYI: No change from May 13 posting)
– Updated: Questions and Answers for Patients (FYI: No change from May 13 posting) |
| May 21 |
Executive Officer Notice: Administration of Second Doses for Individuals who received First Dose of AstraZeneca / COVISHIELD COVID-19 Vaccines in Ontario Pharmacies
– Questions and Answers for Patients |
| May 18 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date May 13, 2021)
(FYI: No change from May 13 posting)
– Updated: Questions and Answers for Pharmacists (FYI: No change from May 13 posting)
– Updated: Questions and Answers for Patients (FYI: No change from May 13 posting) |
| May 13 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 13, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date May 13, 2021)
– Updated: Questions and Answers for Pharmacists
– Updated: Questions and Answers for Patients |
| May 11 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Executive Officer Notice: Pause of the Administration of First Doses of Publicly Funded AstraZeneca / COVISHIELD COVID-19 Vaccines in Ontario Pharmacies |
| May 11 |
Executive Officer Notice: Updated Income Eligibility Thresholds for the Seniors Co-Payment Program under the Ontario Drug Benefit Program
– Questions and Answers for Pharmacists
– Questions and Answers for Patients |
| May 6 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice. Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date May 6, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
– Questions and Answers for Pharmacists (FYI: No change from April 30 posting)
– Questions and Answers for Patients (FYI: No change from April 19 posting) |
| May 5 |
Notice from the Executive Officer: Funding of enoxaparin under the Ontario Drug Benefit Program
– Frequently Asked Questions |
| April 30 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date April 30, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date April 30, 2021)
– Updated Questions and Answers for Pharmacists
– Questions and Answers for Patients (FYI: No change from April 19 posting) |
| April 23 |
* Please refer to entry posted on May 31 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers
Updated Executive Officer Notice: Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria |
| April 19 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date April 19, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date April 19, 2021)
– Questions and Answers for Pharmacists
– Questions and Answers for Patients |
| April 16 |
Executive Officer Notice of interim change to Extemporaneous Preparations Policy for Anti-infectives for Post-Hospital Use |
| April 15 |
Executive Officer Notice: Proposed Legislative and Regulatory Amendments - Dissolution of the Citizens’ Council and the Pharmacy Council under the Ontario Drug Benefit Act |
| April 7 |
* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers
Updated: Executive Officer Notice: Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria |
| April 1 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date April 1, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date April 1, 2021)
– Questions and Answers for Pharmacists
– Questions and Answers for Patients |
| March 26 |
Executive Officer Notice: Proposal to update the Income Eligibility Thresholds for the Seniors Co-Payment Program under the Ontario Drug Benefit Program |
| March 25 |
Notice from the Executive Officer: Funding of Adalimumab under the Ontario Drug Benefit Program
– Frequently Asked Questions |
| March 22 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Eligibility
(Effective date March 22, 2021)
Updated: Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies – Billing
(Effective date March 22, 2021)
– Questions and Answers for Pharmacists
– Questions and Answers for Patients |
| March 18 |
Notice from the Executive Officer: The Ontario Drug Programs Reference Manual, Revision #2
Notice from the Executive Officer: Regulatory Amendments relating to Recordkeeping Requirements for Pharmacies and Dispensing Physicians under the Ontario Drug Benefit Program
– Questions and Answers |
| March 16 |
Executive Officer Notice: Update of the OPDP At A Glance Report |
| March 10 |
* Please refer to entry posted on April 6, 2023 for the latest updated EO Notice.
Executive Officer Notice: Administration of Publicly Funded COVID-19 Vaccine in Ontario Pharmacies
(Effective date March 10, 2021)
– Questions and Answers for Pharmacists
– Questions and Answers for Patients |
| March 5 |
* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers
UpdatedExecutive Officer Notice: Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies: Eligibility Criteria |
| March 5 |
Notice from the Executive Officer: Reconciliation Adjustment Percentages for 2021/22 to Improve the Value of Pharmacy Payments |
| February 19 |
* Please refer to entry posted on April 23, 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers
Executive Officer Notice: Expansion of Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies (Eligibility and Investigation Numbers)
(Effective February 19, 2021)
Updated Executive Officer Notice: Expansion of Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies (Billing, Pharmacy Record Documentation)
(Effective February 19, 2021)
– Updated Questions and Answers for Pharmacists
– Updated Questions and Answers for Patients
|
| January 25 |
Notice from the Executive Officer: Funding of Insulin Lispro under the Ontario Drug Benefit Program
– Questions and Answers |
| January 15 |
Executive Officer Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020
– Questions and Answers for Pharmacists |
| 2020 |
| December 18 |
Executive Officer Notice: Administering the Flu Vaccine to Children Age 2 and older under the Universal Influenza Immunization Program 2020/21 |
| December 18 |
Executive Officer Notice: Funding of Avsola (Infliximab) under the Ontario Drug Benefit Program
– Questions and Answers |
| December 14 |
Executive Officer Notice: Update to Drug Benefit Claim - Submission/Reversal Forms
– Questions and Answers |
| December 14 |
Executive Officer Notice: Update to Special Authorization – Allergen (SAA) Form |
| December 8 |
* Please refer to entry posted on April 23 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers
** Please refer to entry posted on February 19, 2021 for the latest updated EO Notice on Billing and Pharmacy / Patient Qs and As
Executive Officer Notice: Update - Expansion of Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies
(Effective December 11, 2020)
– Questions and Answers for Pharmacists
– Questions and Answers for Patients |
| December 7 |
Executive Officer Notice: Fluarix influenza vaccine injection added to the Universal Influenza Immunization Program 2020/21 for Pharmacists Administering Flu Vaccines |
| November 30 |
Executive Officer Notice: FluMist Nasal Spray added to the Universal Influenza Immunization Program 2020/21 for Pharmacists Administering Flu Vaccines |
| November 20 |
Executive Officer Notice: Forgery Notification Alerts in the Health Network System (HNS), including the Narcotics Monitoring System (NMS)
– Questions and Answers |
| November 5 |
* Please refer to entry posted on April 23 2021 for the latest updated EO Notice on Eligibility and Investigation Numbers
** Please refer to entry posted on February 19, 2021 for the latest updated EO Notice on Billing and Pharmacy / Patient Qs and As
Notice from the Executive Officer: Expansion of Specimen Collection for COVID-19 Testing of At-Risk Asymptomatic Persons through Ontario Pharmacies
– Questions and Answers for Pharmacists
– Questions and Answers for Patients |
| October 26 |
Notice from the Executive Officer: Updates to Pharmacists Administering Flu Vaccine to patients without a Health card number |
| October 26 |
Notice from the Executive Officer: Reminder to pharmacies on extensions to expiry dates on Ontario health card numbers |
| October 22 |
Notice from the Executive Officer: Proposal to Streamline Recordkeeping Requirements for Pharmacies and Dispensing Physicians under the Ontario Drug Benefit Program |
| October 21 |
Executive Officer Notice: Funding of Emeradeâ„¢ (Epinephrine Auto-Injector) through the Allergen Program |
| October 6 |
Executive Officer Notice: Proposal to Improve Access to
Exceptional Access Program Drugs for Ontarians
Living Near Manitoba and Quebec Borders |
| October 2 |
Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System
– Frequently Asked Questions |
| August 24 |
Executive Officer Notice: Funding of Riximyo (rituximab) and Ruxience (rituximab) under the Ontario Drug Benefit Program
– Frequently Asked Questions |
| August 5 |
Executive Officer Notice: Funding of Allerject® (Epinephrine Auto-Injector) through the Allergen Program
|
| July 30 |
Executive Officer Notice: Inspections Return to Work |
| June 12 |
Executive Officer Notice: Removal of the 30-days' Supply Dispensing Limit Recommendation
– Frequently Asked Questions |
| May 21 |
Notice from the Executive Officer: Funding of Teva UK-labelled Salamol CFC-Free (Salbutamol Sulfate) Inhaler as a Temporary Benefit on the Ontario Drug Benefit (ODB) Formulary. |
| May 13 |
Notice from the Executive Officer: Regulatory Amendments to Ontario Drug Benefit Program Co-payments
– Frequently Asked Questions |
| May 13 |
Notice from the Executive Officer: Changes to the Trillium Drug Program in Response to COVID-19
– Frequently Asked Questions |
| May 1 |
Notice from the Executive Officer: Proposed Regulatory Amendments to Ontario Drug Benefit (ODB) Program Co-payments and Dispensing Fees |
| April 23 |
Notice from the Executive Officer: Brand Reference Price Regulations Amendment |
| April 23 |
Notice from the Executive Officer: Drug Submissions for Ontario Drug Benefit (ODB) Program during the COVID-19 Public Health Emergency |
| April 15 |
* Please also refer to entry December 12 under 2022 for latest information on the Ontario Naloxone Program for Pharmacies (ONPP) in regards to the Quarterly Report Back Form.
Executive Officer Notice: Updated Quarterly Report Back Form for the Ontario Naloxone Program for Pharmacies (ONPP)
– Questions and Answers for the Updated QRBF
– Quarterly Report Back Form |
| April 15 |
Notice: Ontario Drug Benefit Program and Exceptional Access Program Changes during the COVID-19 Public Health Emergency |
| April 7 |
Notice from the Executive Officer: Regulation Amendments to Private Label Products and Brand Reference Pricing Rules |
| April 1 |
Notice: Extending Submission Period for Electronic Drug Claim Reversals AND The Ontario Drug Programs Reference Manual, Revision #1
– Frequently Asked Questions |
| April 1 |
Notice: Policy for Methadone Maintenance Treatment Reimbursement under the Ontario Drug Benefit Program
– Frequently Asked Questions for Pharmacists |
| March 30 |
Notice from the Executive Officer: Proposed amendments to the effective date of changes to allow Private Label Products to be funded under the Ontario Drug Benefit (ODB) Program and Designated as Interchangeable Products on the ODB Formulary |
| March 30 |
Notice from the Executive Officer: Proposed Regulatory Amendments on Rules for Determining Brand Reference Prices |
| March 30 |
Notice from the Executive Officer: Funding of Truxima (rituximab) under the Ontario Drug Benefit Program
– Frequently Asked Questions
|
| March 23 |
Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation |
| March 20 |
Notice: Ontario Drug Benefit (ODB) Program Changes and Guidance for Dispensers during the COVID-19 Public Health Emergency |
| March 2 |
Notice: Reconciliation Adjustment Percentages for 2020/21 to Improve the Value of Pharmacy Payments |
| 2019 |
| December 23 |
Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to reduce Administrative Burden to Drug Manufacturers and Pharmacies |
| December 23 |
Notice: Updates to the Ontario Guidelines for Drug Submission and Evaluation Notice |
| December 16 |
Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act and Regulation 935 made under the Drug Interchangeability and Dispensing Fee Act to reduce restrictions on Private Label Products and Ordinary Commercial Term benefits
|
| December 16 |
Notice: Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020
* Please refer to entry posted on September 21, 2021 for an amendment to the Policy effective September 27, 2021
– Frequently Asked Questions
– Key Facts for Pharmacists
– Key Facts for Patients and Families
– Attestation Notice of Change in LTC Home Primary Pharmacy Service Provider Form
|
| December 16 |
Notice: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Improve the Value of Pharmacy Payments
– Frequently Asked Questions for Pharmacists |
| October 28 |
Notice: Proposal to Improve the Value of Pharmacy Payments |
| October 28 |
Notice from the Executive Officer: Proposal to Reduce Administrative Burden to Drug Manufacturers and Pharmacies |
| October 18 |
Notice from the Executive Officer: Pharmacist administration of publicly funded influenza vaccines and claims submission using the Health Network System
– Frequently Asked Questions |
| October 1 |
Notice from the Executive Officer: Updates to the Drug Evaluation Process for Biosimilar Products |
| September 12 |
Notice from the Executive Officer: Funding Flash Glucose Monitoring System Through the Ontario Drug Benefit Program |
| July 31 |
Notice from the Executive Officer: Updated Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program
– Frequently Asked Questions
|
| July 24 |
Notice from the Executive Officer Submission Requirements: Flash GlucoseMonitoring (FGM) |
| July 4 |
Notice from the Executive Officer: Updates to the Ontario Guidelines for Drug Submission and Evaluation |
| June 4 |
Notice from the Executive Officer: Change to the Health Network System Subscription Agreement for Pharmacy Operators |
| April 26 |
Notice from the Executive Officer: Proposals to Establish More Efficient Pharmacy Reimbursement Policies |
| March 13 |
Notice from the Executive Officer: Buprenorphine/Naloxone (Suboxone® and generics) Reimbursement Reminder under the Ontario Drug Benefit Program |
| February 27 |
Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to make changes to Ontario Drug Benefit Program coverage for children and youth aged 24 years and under (OHIP+)
– Frequently Asked Questions for Patients
– Frequently Asked Questions for Pharmacists |
| February 13 |
Notice from the Executive Officer: Extension of the Temporary Facilitated Access Mechanism (Rheumatology) until March 31, 2019) |
| February 1 |
Notice from the Executive Officer: Administrative Monetary Penalty Issued for Acceptance of Rebates
– Rebate Order
|
| January 2 |
Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to make changes to Ontario Drug Benefit Program coverage for children and youth aged 24 years and under (OHIP+) |
| 2018 |
| December 31 |
Notice from the Executive Officer: Interim Extension of the Temporary Facilitated Access Mechanism (Rheumatology) |
| December 4 |
Notice from the Executive Officer: Completion of Strengthening Pharmacy Payment Management |
| October 29 |
Notice from the Executive Officer: Proposed Amendments to Regulations under the Ontario Drug Benefit Act and the Drug Interchangeability and Dispensing Fee Act relating to Private Label Products |
| October 4 |
Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines and Claims Submission using the Health Network System
– Frequently Asked Questions |
| September 25 |
Notice from the Executive Officer: Update on Claims Submission for Valved Holding Chambers through the Ontario Drug Benefit Program |
| September 20 |
Notice from the Executive Officer: Funding of Renflexis (infliximab) under the Ontario Drug Benefit Program
– Frequently Asked Questions |
| September 20 |
Notice from the Executive Officer: Funding of Glatect (glatiramer acetate) under the Ontario Drug Benefit Program
– Frequently Asked Questions |
September 10
(Updated October 11) |
Notice from the Executive Officer: Availability and Funding of AUVI-Q® (Epinephrine Auto-Injectors) as a Result of the Shortage of EpiPen® Products. |
| August 14 |
Notice from the Executive Officer: Claim Submission/Reversal and Special Authorization (Allergen) forms |
| July 30 |
Notice from the Executive Officer: Update on OHIP+ |
| May 4 |
Notice from the Executive Officer: Refreshed ODB Report Card |
| May 1 |
Notice from the Executive Officer: Update Regarding Strengthening Pharmacy Payment Management |
March 29
(Updated
October 12) |
Notice from the Executive Officer: Changes in the Way Pharmacies Verify Eligibility for Individuals Receiving Social Assistance
– Identification you can use to get health services
– How to Register Your Pharmacy for the SAV Portal
– SAV Portal Info Sheet |
March 21
(Updated April 27) |
* Please also refer to entry December 12, 2022 for new information on the Ontario Naloxone Program for Pharmacies (ONPP) in regards to the Quarterly Report Back Form.
Notice from the Executive Officer: Funding of Naloxone Nasal Spray through the ONPP and Updates to the Existing Program
– Frequently Asked Questions
– Instructional Insert |
| March 8 |
Notice from the Executive Officer: Funding of Naloxone Nasal Spray through the ONPP
– Frequently Asked Questions |
| March 5 |
Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs |
| March 2 |
Notice from the Executive Officer: Ontario Drug Benefit Act Regulatory Amendment to Support the Ontario Basic Income Pilot (OBIP)
– Frequently Asked Questions |
| February 21 |
Notice from the Executive Officer: Funding of Hepatitis B Drugs under the Ontario Drug Benefit Program
– Frequently Asked Questions |
| February 8 |
Notice from the Executive Officer: Addition of Nurse Practitioners to the Palliative Care Facilitated Access (PCFA) Mechanism |
| January 24 |
Notice from the Executive Officer: Edition 43 of the Ontario Drug Benefit Formulary |
| January 16 |
Notice from the Executive Officer: Ontario Drug Benefit Act Proposed Regulatory Amendments to Align Maximum Days’ Supply of Prescriptions Dispensed for Ontario Works Recipients 25 years of Age and Older |
| January 10 |
Notice from the Executive Officer: Ontario Drug Benefit Act Proposed Regulatory Amendment to Support the Ontario Basic Income Pilot (OBIP)
– Frequently Asked Questions |
| 2017 |
| December 22 |
Notice from the Executive Officer: Drug Submission – Submission Requirements: Valved Holding Chambers (VHCs) |
| December 21 |
Notice from the Executive Officer: Funding Valved-Holding Chambers through the Ontario Drug Benefit Program |
| December 14 |
Notice from the Executive Officer: Funding of Erelzi (etanercept) under the Ontario Drug Benefit Program
– Frequently Asked Questions |
| December 14 |
Notice from the Executive Officer: Temporary Facilitated Access Mechanism (Rheumatology) for Ontario Drug Benefit Recipients aged 24 years and under |
| December 1 |
Notice from the Executive Officer: Removal of the Special Authorization (Allergen) Form for Pharmacy Dispensing of Epinephrine Auto-Injectors for Ontario Drug Benefit recipients |
| November 17 |
Addendum: Notice from the Executive Officer: Addition of Agriflu® to the Universal Influenza Immunization Program |
| October 13 |
Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines and Claims Submission using the Health Network System for the 2017/2018 Influenza Immunization Season
– Frequently Asked Questions |
| September 21 |
Notice from the Executive Officer: Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for the Fentanyl Transdermal Patch
– Frequently Asked Questions |
| September 21 |
Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Support the Homes for Special Care Modernization Initiative |
| September 1 |
Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management
|
| September 1 |
Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare
|
| August 23 |
Notice from the Executive Officer: Notice from the Executive Officer: Thyroid (Desiccated Thyroid) Delisting
|
| August 3 |
Notice from the Executive Officer: Funding of Mifepristone/Misoprostol (Mifegymiso)
(updated December 7, 2017)
– Frequently Asked Questions for Health Care Providers (updated December 7, 2017)
– Frequently Asked Questions for Patients (updated December 7, 2017)
|
| August 1 |
Notice from the Executive Officer: Funding of filgrastim under the Ontario Drug Benefit Program
– Frequently Asked Questions
|
| July 21 |
Notice from the Executive Officer: Funding of Brenzys (etanercept) under the Ontario Drug Benefit Program
– Frequently Asked Questions
|
| July 11 |
Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare Program
|
| July 7 |
Notice from the Executive Officer: Ontario Drug Benefit Act, Legislative amendments to recognize the role of Nurse Practitioners in requesting Exceptional Access Program products and prescribing Listed Substances (Bill 87)
– Frequently Asked Questions for Health Care Providers
|
| June 29 |
Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management
|
| March 16 |
Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs
|
| February 21 |
Notice from the Executive Officer: Funding of Hepatitis C drug products under the Ontario Drug Benefit Program
– Frequently Asked Questions for Health Care Providers
– Frequently Asked Questions for Patients
|
| January 27 |
Notice from the Executive Officer: Updated Reminder Regarding Delisting of High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program |
| 2016 |
| December 21 |
Notice from the Executive Officer: Funding of Grastofil (filgrastim) under the Ontario Drug Benefit program
– Frequently Asked Questions |
| December 1 |
Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program
– Frequently Asked Questions |
| November 30 |
Notice from the Executive Officer: Update Regarding Palliative Care Access to High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program |
| October 24 |
Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines for 2016-2017 Season and Claims Submission using the Health Network System
– Frequently Asked Questions |
| October 07 |
Notice from the Executive Officer: Application of Generic Substitution to the Exceptional Access Program
– Frequently Asked Questions for Patients
– Frequently Asked Questions for Pharmacists
– Frequently Asked Questions for Physicians
|
| September 26 |
Notice from the Executive Officer: Regulation amendments to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products |
| September 16 |
Notice from the Executive Officer: Regulation to support the Safeguarding our Communities Act, 2015 (Patch for Patch Return Program)
– Frequently Asked Questions for Prescribers and Pharmacists |
| September 16 |
Notice from the Executive Officer: Drug Submission – Ontario Guidelines for Drug Submission and Evaluation 2016 |
| September 02 |
Notice from the Executive Officer: Changes in the Way Social Assistance Clients Access Drug Coverage
– Updated Drug Eligibility Card Pharmacy Information Sheet
– Updated User Guide
– Updated ODB Cannot be confirmed via HNS
– Updated ODB Cannot be confirmed via HNS– Accessible version
– Drug Eligibility Pharmacy Quick Reference Guide
– Drug Eligibility Pharmacy Questions and Answers
For Social Assistance Clients
– Drug Eligibility Card Client Information Sheet
– Social Assistance Client Cheque Insert - Aug./Sept. version
– Social Assistance Client Cheque Insert - Oct./Nov. version
|
| August 17 (Updated April 27) |
* Please refer to entry December 12, 2022 for current information on the Ontario Naloxone Program for Pharmacies (ONPP). The materials below are available below for reference purposes.
* Please also refer to entry April 15 under 2020 for new information in regards to the Quarterly Report Back Form.
Notice from the Executive Officer: Reminder - Ontario Naloxone Program for Pharmacies (ONPP)
Notice from the Executive Officer: Ontario Naloxone Program for Pharmacies (ONPP)
– Frequently Asked Questions for Pharmacists |
| August 15 |
* Please also refer to entry April 1 under 2022 for new information on the Medical Assistance in Dying Program. The materials below are available below for reference purposes.
Notice from the Executive Officer: Reimbursement and Claims Submissions using the Health Network System relating to Drugs for Medical Assistance in Dying
– Frequently Asked Questions for Pharmacists |
| July 20 |
Notice from the Executive Officer: Changes to the Ontario Drug Benefit (ODB) Program Funding of Opioid Medications
– Frequently Asked Questions for Pharmacists |
| July 4 |
Notice from the Executive Officer: MedsCheck Program Enhancements |
| June 10 |
Notice from the Executive Officer: Health Network System (HNS) Changes to Support the Maximizing Quantity Dispensed for Chronic-Use Medications Initiative
– Frequently Asked Questions |
| June 1 |
Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products |
| June 1 |
Notice from the Executive Officer: Proposed Regulation under the Safeguarding our Communities Act (Patch for Patch Return Policy) |
| April 15 |
Notice from the Executive Officer: Regulation Amendments to Expand Access to the Seniors’ Co-Payment Program under the Ontario Drug Benefit (ODB) Program |
| March 22 |
Executive Officer Notice Drug Submission – Information Bulletin |
| March 15 |
Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs |
| March 11 |
Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program
– Frequently Asked Questions |
| February 29 |
Notice from the Executive Officer:Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act to update cost-sharing arrangements for non-low income seniors under the Ontario Drug Benefit (ODB) program |
| 2015 |
| November 23 |
Notice from the Executive Officer: New Blood Glucose Test Strip Reimbursement Policy |
| November 13 |
Notice from the Executive Officer: Claims submission for prescriptions with drug costs over $10,000
– Frequently Asked Questions |
| October 13 |
Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2015-2016 Season and Claims Submission using the Health Network System
– Frequently Asked Questions updated October 2015 |
| September 18 |
Notice from the Executive Officer: Regulation Amendments to Streamline Submission Requirements for Certain Generic Products seeking Interchangeability Designations on the Ontario Drug Benefit Formulary |
| September 18 |
Notice from the Executive Officer: Regulation Amendments to Support Sustainability and Access for the Ontario Public Drug Programs |
| September 18 |
Notice from the Executive Officer: Supporting Sustainability and Access for the Ontario Drug Benefit Program
– Questions & Answers for Pharmacists
– Questions & Answers for Physicians
– Questions & Answers for Patients
– Chronic-use Medications List by Generic Name |
| July 23 |
Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act
–
Questions & Answers for Patients |
| May 20 |
Notice from the Executive Officer: Tiered Generic Pricing Framework |
| March 10 |
Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs |
| 2014 |
| November 5, 2014 |
Notice from the Executive Officer: Proposed Regulation Amendments to Establish a Pricing Framework for Certain Generic Products on the Ontario Drug Benefit (ODB) Formulary
English | French |
| October 10 |
Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2014-2015 Season and Claims Submission using the Health Network System
English | French
–
Frequently Asked Questions updated November 21, 2014
English | French |
| March 11 |
Notice from the Executive Officer: Reminder of the Upcoming Changes for April 1, 2014 [PDF] |
| March 10 |
Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs [PDF] |
| 2013 |
| November 28 |
Notice from the Executive Officer: Edition 42 of the Ontario Drug Benefit Formulary [PDF] |
| November 26 |
Notice from the Executive Officer: Accuracy in Claims Submissions [PDF] |
| October 4 |
Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2013-2014 Season and Claims Submission using the Health Network System
english | french |
| September 17 |
Blood Glucose Test Strip Reimbursement Update [PDF] |
| July 11 |
Notice to Pharmacies - Contacting the ODB Help Desk [PDF] |
| July 8 |
Notice from the Executive Officer: Blood Glucose Test Strip Reimbursement Policy [PDF]
english | french |
| June 11 |
Notice from the Executive Officer: Professional Allowances Reporting Template for Drug Manufacturers [Excel] |
| March 7 |
Notice from the Executive Officer: Reminder of the Upcoming Changes for April 1, 2013 |
| March 4 |
Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs |
| February 20 |
Important Notice from the Executive Officer: Proper Submission of Prescriber Identification to the Health Network System (HNS) and Narcotics Monitoring System (NMS) [PDF] |
| February 13 |
Notice from the Executive Officer: Professional Allowances Reporting Template for Drug Manufacturers [Excel] |
| February 4 |
Notice from the Executive Officer: FINAL Reminder Regarding the Funding Status of Oxycodone Controlled Release Tablet – OxyNEO [PDF] |
| January 24 |
Notice from the Executive Officer: New Regulatory Requirements for Long-Acting Oxycodone Drug Products [PDF] |
| January 15 |
Notice from the Executive Officer: Assignment of ON Numbers to Health Network System/Ontario Drug Benefit Accounts |
| 2012 |
| December 20 |
Notice from the Executive Officer: Expanded Scope of Practice and Accuracy in Claims Submission [PDF] |
| December 12 |
Delisting of Aliskiren (Rasilez®) from the ODB Formulary - Questions & Answers |
| November 28 |
Important notice regarding the prescribing and dispensing of Oxycodone CR.
english | french |
| November 23 |
Proposed Regulation Amendments to Set Additional Conditions for Submission Requirements of Long-Acting Oxycodone Drug Products
english | french |
| October 10 |
Notice to Pharmacies – Contacting the Help Desk [PDF] |
| October 9 |
Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System; 2012-2013 Influenza Season
- Fact Sheet
- Q & As |
| October 4 |
Notice from the Executive Officer: Important Reminder Regarding the Funding Status of Oxycodone Controlled Release Tablet - OxyNEO [PDF] |
| September 27 |
Notice from the Executive Officer: Changes to the Transition Fee Payments under the Ontario Drug Benefit (ODB) Program |
| September 24 |
Important Notice from the Executive Officer: Proper Submissions to the Narcotics Monitoring System (NMS) [PDF] |
| August 20 |
Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers [Excel] |
| August 15 |
Proposed Regulation Amendment to Reduce the Transition Fee Payments under the Ontario Drug Benefit (ODB) Program |
| May 8 |
Important Notice from the Executive Officer: Submission of Monitored Drug Information to the Narcotics Monitoring System |
| April 12 |
Notice from the Executive officer. Re: Implementation of the Narcotics Monitoring System (NMS)
english | french |
| March 16 |
Notice from the Executive Officer. Re: Upcoming Changes for April 1, 2012 |
| February 27 |
Notice from the Executive Officer. Re: Pharmaceutical Opinion Program |
| February 17 |
Notice from the Executive Officer: RE: Important Notice Regarding Change in Funding Status of Oxycodone Controlled Release Tablet – (Discontinuation of OxyContin and Introduction of OxyNEO)
english | french |
| February 6 |
Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers |
| 2011 |
| December 6 |
Notice from the Executive officer. Re: Prescriber ID Requirements for Claims Submitted on the Health Network System (HNS) |
| November 30 |
Notice from the Executive Officer. Re: Additional Clarification Regarding the Narcotics Legislation |
| October 27 |
Notice from the Executive Officer. Re: Additional Questions on the Narcotics Legislation
english | french |
| October 14 |
Important Notice to Health Care Providers on the New Requirements under the Narcotics Safety and Awareness Act, 2010 |
| October 14 |
Public Notice Regarding the Ministry of Health and Long-Term Care's ("ministry") Collection, Use and Disclosure of Information under the Narcotics Safety and Awareness Act, 2010
english | french |
| September 9 |
Suspension of Ontario Drug Benefit (ODB) Billing Accounts |
| August 31 |
Notice from the Executive Officer. Re: MedsCheck Program Standardization and system Requirements |
| August 31 |
Notice from the Executive Officer. Re: Pharmaceutical Opinion Program |
| August 29 |
Notice from the Executive Officer. Re: Pharmacy Smoking Cessation Program |
| August 22 |
Notice from the Executive Officer. Re: Expanding Professional Pharmacy Services for September 1, 2011 |
| July 28 |
Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers |
| June 10 |
Notice from the Executive Officer. Re: Extension of Transition Fee Payments and Conditions for Payment of Dispensing Fees for Remote Dispensing Location under the Ontario Public Drug Programs |
| May 24 |
Clarification to the Notice from the Executive Officer. Re: Lucentis – Change in Status to Limited Use (April 1, 2011) |
| April 7 |
Notice from the Executive Officer. Re: New Regulation under the Optometry Act, 1991 |
| April 4 |
Notice from the Executive Officer. Re: Request for Qualification (RFQ) for Acquirer Host Network Services |
| April 1 |
Notice from the Executive Officer. Re: EAP criteria change for rosiglitazone (Avandia) |
| April 1 |
Notice from the Executive Officer. Re: Lucentis - Change in Status to Limited Use |
| March 29 |
Notice from the Executive Officer. Re: Implementation of the first stage of expanded services |
| March 23 |
Notice from the Executive Officer. Re: Expanding Professional Pharmacy Services for April 1, 2011 |
| March 23 |
Notice from the Executive Officer. Re: Increase in Dispensing Fees, Effective April 1, 2011 |
| March 18 |
Notice from the Executive Officer. Re: New Regulation under the Drug and Pharmacies Regulation Act (DPRA) |
| February 28 |
Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers |
| February 09 |
Notice from the Executive Officer. Re: Narcotics Monitoring System Questions and Answers |
| 2010 |
| December 6 |
Notice from the Executive Officer. Re: Formulary Listing for Enalapril Maleate |
| October 19 |
Q & As for Change in Listing Status for Gabapentin |
| September 30 |
Notice from the Executive Officer. Re: Pharmacy ONE Mail System Registration - Reminder Notice |
| September 8 |
Notice from the Executive Officer. RE: MedsCheck Program Expanded Services Launched September 13, 2010 |
| August 26 |
Notice from the Executive Officer: Change in Status to Limited Use (Humira and Enbrel) & New Limited Use Listing (Stelara)
- Q & As for Change in Listing Status for Humira, Enbrel, and Stelara |
| August 23 |
Notice from the Executive Officer. RE: Expanding Professional Pharmacy Services Working Group |
| July 13 |
Notice from the Executive Officer:
Reporting Framework for Professional Allowances |
| June 08 |
Notice from Ontario Public Drug Programs
Re: Clarification of Digoxin Listings |
| January 25 |
Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| 2009 |
| July 17 |
Policy to Acquire Medications for Treatment of Tuberculosis
- Dear Pharmacist Letter. Communiqué from the Public Health Division, MOHLTC |
| July 15 |
Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| May 6 |
Notice from the Executive Officer: Change of Funding Status Rosiglitazone (Avandia®) and Pioglitazone (Actos® and Generics)
- Q&As for TZD Funding Status Change |
| May 6 |
Notice from the Executive Officer: Expanded Limited Use Criteria for Clopidogrel (Plavix)
- Q&As for Clopidogrel Expanded LU Criteria |
| March 3 |
Notice from the Executive Officer - MedsCheck Adjustment Payment to Pharmacies Ending on April 1, 2009 |
| February 23 |
Notice from the Executive Officer: Ongoing Transparency Initiative: Public Posting of Drug Submission Status - Updates |
| February 4 |
Notice from the Executive Officer: Reminder – Professional Allowance Reporting: July 1, 2008 to December 31, 2008 |
| January 13 |
Notice from the Executive Officer: Academic Detailing Program
- Q&As for Academic Detailing Program |
| 2008 |
| December 19 |
Notice from the Executive Officer: Health Network System (HNS) Enhancements to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program |
| December 17 |
Notice from the Executive Officer: Renewal of the Health Network System (HNS) Subscription Agreement |
| December 1 |
Notice from the Executive Officer: Enhancements to Health Network System to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program |
| December 1 |
Notice from the Executive Officer: Announcement of Changes to the Formulary respecting Enalapril Maleate |
| November 17 |
Notice from the Executive Officer: Telephone Request Service for Exceptional Access Program
- Q&As for External Stakeholders |
| October 29 |
Executive Officer Notice: Completing the New Health Network System (HNS) Agreement |
| October 27 |
Executive Officer Notice: Price Increase Requests |
| October 20 |
Notice of Termination and Replacement of Agreement: Ontario Public Drug Programs Subscription Agreement |
| October 3 |
Notice from the Executive Officer: Public Consultation to Review the definition of Professional Allowance and the Codes of Conduct |
| October 2 |
Notice from the Executive Officer: Notice of Termination and Replacement of Agreement: Ontario Public Drug Programs Subscription Agreement |
| September 30 |
Notice From Executive Officer: Implementation Plan To Review The Definition Of Professional Allowance And The Code Of Conduct |
| September 19 |
Notice from the Executive Officer: Notice Of Cancellation Of Call For Application For Ranitidine Hydrochloride |
| August 26 |
Notice from the Executive Officer: Drug Submissions Requirement - Revised Letter of Consent |
| August 22 |
Notice from the Executive Officer Reminder - Professional Allowance Reporting |
| August 5 |
Notice from the Executive Officer: Claims for ZANTAC® under the Ontario Drug Benefit Program |
| July 28 |
Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program
- Questions and Answers |
| July 18 |
Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| July 16 |
Notice from the Executive Officer: Competitive Agreements Q&As |
| July 8 |
Notice from the Executive Officer: Ontario Public Drug Programs Competitive Agreement
- Briefing for Stakeholders |
| June 4 |
Notice from the Executive Officer: Manufacturer Review of Transparency Bulletin |
| May 29 |
Notice from the Executive Officer: Pricing of Products Reimbursed Under the Exceptional Access Program (EAP) |
| May 16 |
Notice from Executive Officer |
| May 16 |
Notice from Executive Officer: Limited Use (LU) Process Changes |
| May 13 |
Notice from Executive Officer: Ongoing Transparency Initiative - Public Posting of Drug Submission Status. |
| April 17 |
Notice from the Executive Officer: Lucentis Questions and Answers |
| April 15 |
Recruitment for Pharmacy Council Members, letter from the Executive Officer |
| March 6 |
Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| January 30 |
2008 BBS Notice from the Executive Officer: MedsCheck, Adjustment Payment to Pharmacies - a Reminder |
| 2007 |
| November 15 |
Notice from the Executive Officer, BBS Introducing the "Follow-up" MedsCheck, effective November 30, 2007 |
| November 15 |
Recruitment for Pharmacy Council Members, letter from the Executive Officer |
| November 13 |
Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| October 19 |
Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| October 1 |
Notice to Manufacturers Submission Requirements for Generic Drug Products |
October 4
|
(BBS Nº.7079)
Notice from the Executive Officer: Lead Time Between the Formulary Update and Effective Date |
| September 14 |
(BBS Nº.7071)
Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| July |
Letter to Pharmacists from the Executive Officer: MedsCheck Update |
| July 13 |
Notice to Pharmacists: MedsCheck Update |
| May 29 |
(BBS Nº.7029)
MedsCheck Update |
| May 8 |
(BBS Nº.7025)
Notice to Pharmacists from Executive Officer: Follow up to April 5, 2007 Notice |
| April 1 |
Letter to Pharmacists from the Executive Officer: MedsCheck |
| February 21 |
(BBS Nº.7009)
Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| 2006 |
| December 18 |
(BBS Nº.6086)
Notice from the Executive Officer: Amending Regulations under ODBA and DIDFA |
| September 28 |
Notice to Pharmacists: Regulation Changes made to the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA) |
| April 13 |
(BBS Nº.6029)
Notice to Pharmacists: Bill 102, Transparent Drug System for Patients Act |
Public Information
